Proprietary Therapeutic Pipeline

Two Proprietary Oncology Programs.
One Integrated Discovery Platform.

CycloGen AI is advancing two internally directed oncology discovery programs through its integrated Structural Intelligence and AI-powered molecular discovery platform. Our research combines structure-guided molecular analysis, computational design, and systematic candidate evaluation to pursue differentiated small-molecule therapeutic opportunities.

Program
Target Selection
Computational Discovery
Experimental Validation
Lead Optimization
Preclinical
Clinical
CG-ONC-001
Oncology — Undisclosed Target
Small Molecule
Computational Discovery
Target SelectionClinical
Experimental Validation: In Planning
Computational Discovery Validation in Planning
CG-ONC-002
Oncology — Undisclosed Target
Small Molecule
Exploratory Discovery
Target SelectionClinical
Experimental Validation: In Planning
Exploratory Discovery Validation in Planning
Completed
Active
Planned

Development Status

Programs are in early-stage computational discovery. Experimental validation activities are being coordinated with external research collaborators.

Internally Directed Discovery. Long-Term Therapeutic Opportunity.

CycloGen AI's proprietary oncology programs complement its enterprise molecular discovery platform by creating opportunities for internally developed therapeutic intellectual property. The company applies its integrated computational capabilities to prioritize molecular discovery opportunities and support evidence-driven research decisions.

Internal Discovery Programs

Two oncology-focused small-molecule research programs advancing through computational discovery.

Integrated Discovery Technology

Structural Intelligence, molecular design, and systematic computational evaluation capabilities.

Future Therapeutic Opportunities

Potential intellectual property, pharmaceutical collaborations, and co-development arrangements.

Connecting Computational Discovery With Experimental Science

CycloGen AI is coordinating with specialized external research collaborators to establish experimental evaluation activities for its proprietary discovery programs. Our collaboration network provides a potential pathway from computational candidate evaluation to laboratory-generated evidence.

1

Computational Discovery

Structure-guided molecular analysis, candidate generation, and computational evaluation.

→
2

Experimental Evaluation

Planned biochemical and laboratory studies through qualified external research providers.

→
3

Discovery Advancement

Evidence-informed candidate prioritization, potential lead optimization, and future decisions.

Partner With CycloGen AI

CycloGen AI welcomes discussions with pharmaceutical companies, biotechnology organizations, research collaborators, and strategic investors interested in AI-enabled molecular discovery and emerging proprietary therapeutic opportunities.

Explore Investment Opportunities

Learn more about CycloGen AI's enterprise technology platform, commercial strategy, and emerging proprietary discovery portfolio.

Investor Relations

Explore Discovery Partnerships

Discuss opportunities for computational discovery, experimental research collaboration, and future therapeutic co-development.

Discuss a Partnership

Enterprise AI Drug Discovery Platform

CycloGen AI Discovery Pipeline

AI-Powered Drug Discovery Pipeline

CycloGen connects structural biology, AI and computational chemistry across early-stage discovery — from target identification through structure prediction, druggability analysis, molecular design and candidate prioritization for experimental validation.

Build computational evidence before committing candidates to experimental investigation.

01

Target & Structure

Import experimental structures or generate computational structural models and establish structural context for the target.

→
02

Druggability & Pockets

Analyze structural features and potential interaction sites relevant to therapeutic investigation.

→
03

Therapeutic Design

Generate and evaluate candidates: small molecules, nanobodies, antibodies, mini-binders, peptides, protein therapeutics.

→
04

Complex Modeling & Docking

Investigate candidate-target interactions using structural modeling, docking and interface-analysis workflows.

→
05

Candidate Intelligence

Compare computational evidence including structural quality, molecular interactions, and developability to prioritize candidates.

→
06

Experimental Handoff

Export selected computational candidates and supporting evidence for downstream experimental investigation.

Computational Prioritization

Reduce the Search Space Before the Wet Lab

Drug discovery can begin with an enormous number of possible molecules, sequences and therapeutic designs. The purpose of computational discovery is not simply to generate more candidates.

CycloGen helps scientists progressively evaluate and prioritize computational candidates before higher-cost experimental work begins.

Large Design Space
↓
Structural Filtering
↓
Interaction Analysis
↓
Developability Assessment
↓
Prioritized Experimental Set

Protect the Research Behind the Pipeline

Your Discovery Data Can Be Part of Your Intellectual Property

Drug discovery creates valuable intellectual property long before a therapeutic candidate reaches the clinic. Novel biological targets, unpublished protein sequences, molecular designs, antibody candidates, binding hypotheses, structural models and experimental results can represent years of research and significant investment.

Organizations handling confidential research should understand:

Where is the data processed?

Where is it stored?

How long is it retained?

Which subprocessors may handle it?

Which jurisdiction applies?

What contractual confidentiality protections exist?

Private AI Infrastructure

Your Science. Your Infrastructure.

Bring AI-assisted drug discovery closer to the infrastructure that protects your research.

CycloGen Private Deployment

  • Customer-controlled computational environment
  • Local compute options
  • Greater control over research-data movement
  • Integration with internal infrastructure
  • Reduced dependence on external inference services
  • Designed for proprietary research workflows

Externally Hosted Computation

  • Research data may leave internal infrastructure
  • Data-processing terms require review
  • Retention policies vary
  • Data residency may matter
  • External availability can affect workflows
  • Usage or compute limits may apply
Customer-Controlled Environment
Proprietary Target ↓ CycloGen AI ↓ Structure / Design ↓ Computational Analysis ↓ Candidate Results

Computational workflows can remain within infrastructure controlled by the organization, depending on deployment configuration.

Built for Discovery Organizations

Emerging Biotech

Access advanced computational discovery capabilities without having to build every AI and computational infrastructure component internally.

Pharmaceutical R&D

Deploy computational capabilities closer to proprietary research environments and established scientific workflows.

CROs

Extend computational discovery capabilities alongside existing experimental and research services.

One Platform. Different Discovery Environments.

Computational → Experimental

When Candidates Are Ready for the Lab

Computational prediction is the beginning of evidence, not the end. Selected candidates can move from CycloGen computational workflows into appropriately designed experimental programs.

For organizations that need experimental capabilities, CycloGen offers integrated discovery programs using laboratory services delivered through our CRO partner network.

CycloGen AI
Target → Structure → Design → Analysis → Candidate
→
Selected Candidates
→
CRO Partner Network
Production → Assays → Characterization → Evidence

From Computational Hypothesis to Experimental Decision

CycloGen is designed to help scientists reduce large computational design spaces into smaller, traceable sets of candidates for experimental investigation.

Computational prediction does not replace experimental validation. It helps scientists decide what deserves to be tested.